Regeneron Pharmaceuticals (NQ: REGN )

462.21 USD -5.82 (-1.24%)

Streaming Delayed Price Updated: 1:04 PM EST, Feb 24, 2021 Add to My Watchlist

Price and Volume

Volume	452,170
Open	466.11
Bid (Size)	462.03 (1)
Ask (Size)	462.28 (2)
Prev. Close	468.03
Today's Range	462.04 - 469.47
52wk Range	386.83 - 664.64
Shares Outstanding	105,949,824
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

Today 11:00 EST

Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

Today 11:00 EST

FN Media Group Presents USA News Group News Commentary

Performance

YTD	-4.28%	-4.28%
1 Month	-15.69%	-15.69%
3 Month	-8.67%	-8.67%
6 Month	-24.29%	-24.29%
1 Year	+8.66%	+8.66%

More News

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

February 22, 2021

FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

February 22, 2021

Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

February 17, 2021

Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

February 17, 2021

RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today

Today 8:17 EST

Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder

Today 7:21 EST

Why You Should Keep Your Distance from Ocugen Stock

February 23, 2021

Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

February 23, 2021

FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer

February 23, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.